Uncovering the root cause of contamination and leveraging the collaborative learning loop of QbD -Aegis Whitepaper

The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for shortened drug approval review time.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The warning letters deal with a range of violations involving items from personal hygienic products to mismarketed analgesics.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.

The quickly evolving development of biopharmaceuticals is impacting innovation in the industry overall.